Surrozen
SRZN | NASDAQ
$32.32
+$0.71 (+2.25%)
At close: Nov 16, 2026, 4:00 PM ET
$32.32
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
+2.25%
(1D)No price chart data available for 1D timeframe.
Rating
33.8
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #690/1021 (Top 68%)
Key Statistics
Market Data
Market Cap $380.54M
1D Range
30.86 33.09
52W Range
12.80 34.13
Valuation (TTM)
PE -0.69
PB -1.13
EV/EBITDA -0.73
Valuation (NTM)
Forward PE N/A
Forward PEG -0.01
Price Target $67.00
Cash Flow
FCF Yield -8.1%
SBC Adj. FCF Yield -10.4%
SBC Impact -29.0%
Margins
Gross Margin 99.4%
Operating Margin -485.4%
FCF Margin -292.3%
Growth (CAGR)
Revenue 3Y | 5Y -5.6% |
16.6%
Dil EPS 3Y | 5Y -52.4% |
-22.2%
FCF 3Y | 5Y -4.4% |
18.8%
Returns
ROA -357.9%
ROE 228.0%
ROIC -52.4%
Financial Health
Net Cash
$100.35M
Current Ratio 7.56
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics t...
Sector Healthcare
Industry Biotechnology
Employees 44
IPO Date Jan 11, 2021
Website www.surrozen.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 9, 2026
EPS
-$11.02
Miss -901.82%
YoY:
-31.82% REV
-$9.87M
Miss -2177.89%
YoY:
-1104.07%Next Earnings
Mar 22, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
3
Consensus
Buy
Price Target
$67.00
Upside
+107.30%
Buy (3)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove SRZN